NCT07631767 Shift Workers' Health Behavior Action Program Across Europe
| NCT ID | NCT07631767 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wageningen University |
| Condition | Night Shift Work |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-05-15 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2026-05-15 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the effects of a Combined Lifestyle Intervention Program (CLIP) on sleep, lifestyle behaviors, obesity risk and health in night-shift workers. The primary objective is to assess the effect of the CLIP on objectively measured sleep duration. Secondary objectives include behavioral outcomes related to sleep, diet, physical activity, and stress, as well as body weight and metabolic outcomes, . It is hypothesized that CLIP participants will show a greater increase in sleep duration than controls, alongside favorable changes in lifestyle and health outcomes.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 21 years * Work ≥ 24 hours per week * Shift work duration \> 3 years and currently doing night shifts * Expected to continue night shiftwork for at least 1 year after inclusion * On average working ≥ 4 night shifts per month * Working generally ≥ 2 consecutive night shifts * In possession of a smartphone and willing to download the study application Exclusion Criteria: * Body Mass Index (BMI) \< 18.5 or \> 40 kg/m2 * Pregnant or lactating * Chronic diseases with ongoing therapy (e.g. renal failure, active hepatitis, cirrhosis, myocardial infarction, chronic obstructive pulmonary disease and cancer) * Current or recent use of medications interfering with sleep, including: Central nervous system stimulants (e.g., Ritalin, Adderall, Modafinil or similar); Chronic use of sleep agents (e.g., benzodiazepine, non-hypnotic benzodiaze-pine, first-generation antihistamine, melatonin receptors agonists or similar); Other medications or combinations significantly affecting sleeping patterns * Recent or ongoing psychotherapy for sleep disorders * Current or recent use of medications affecting appetite or weight regulation, including: Appetite-enhancing/weight-gain medications (e.g., atypical antipsychotics, cor-ticosteroids such as prednisone, mirtazapine or similar); Appetite-suppressing/weight-loss medications (e.g., CNS stimulants such as Ritalin, Adderall, GLP-1 receptors agonists or similar); Other medications or combinations significantly influencing appetite or body weight * Participation in another human trial, lifestyle program or weight loss intervention within the past 3 months * Planned surgical procedure during the study period * History of or planned bariatric surgery/treatment
Frequently Asked Questions
Who can join the NCT07631767 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Night Shift Work. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07631767 currently recruiting?
Yes, NCT07631767 is actively recruiting participants. Visit ClinicalTrials.gov or contact Wageningen University to inquire about joining.
Where is the NCT07631767 trial being conducted?
This trial is being conducted at Bremen, Germany, Bremerhaven, Germany, Rotterdam, Netherlands, Wageningen, Netherlands and 1 additional location.
Who is sponsoring the NCT07631767 clinical trial?
NCT07631767 is sponsored by Wageningen University. The trial plans to enroll 400 participants.